Combined locked nucleic acid and molecular beacon technologies for sensitive detection of the JAK2V617F somatic single-base sequence variant [7]

Clinical Chemistry

Volumn 52, Issue 7, 2006, Pages 1436-1438

  Sidon, Pierre ^a   Heimann, Pierre ^a   Lambert, Frédéric ^b   Dessars, Barbara ^a   Robin, Valérie ^c   El Housni, Hakim ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; JANUS KINASE 2;

DNA PROBE; GENETIC VARIABILITY; HUMAN; LETTER; MOLECULAR BEACON TECHNOLOGY; NUCLEIC ACID TRANSPORT; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SEQUENCE HOMOLOGY; SOMATIC MUTATION; TECHNOLOGY;

FLUORESCENT DYES; HUMANS; INDICATORS AND REAGENTS; JANUS KINASE 2; MOLECULAR PROBE TECHNIQUES; MUTATION; MYELOPROLIFERATIVE DISORDERS; OLIGONUCLEOTIDES, ANTISENSE; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 33745473836     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.066886     Document Type: Letter

References (6)

1. Tyagi S, Kramer FR. Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol 1996;14:303-8.
2. Petersen M, Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol 2003;21:74-81.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
4. Dominguez PL, Kolodney MS. Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens. Oncogene 2005;24:6830-4.
5. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-8.
6. Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006; 107:176-83.